Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 341

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 341
---
6,140.00 to $9,800.00 |
| Tranche 1 trigger price     |     | $          | 2,500.00 |   |     |             | $64.00 to $78.20       |
| Tranche 2 trigger price     |     | $          | 3,000.00 |   |     |             | $77.00 to $94.00       |
| Contractual term (in years) |     |            |      2.9 |   |     |             | 3.9 to 4.0             |
| Volatility                  |     |            |      100 | % |     |             | 90%                    |
| Risk-free interest rate     |     |            |     3.82 | % |     |             | 4.20% to 4.21%         |

F-27

The classification of the
fair value of the earnout liability and derivative liabilities and the change in the fair value measurement using significant inputs (Level
3) for the three months ended March 31, 2025 and for the period from January 1, 2024 through February 14, 2024 for the Predecessor and
February 14, 2024 through December 31, 2024 for the Company is presented below:

| Preferred stock warrant liability (Predecessor): |     | Level 1 |   |     | Level 2 |   |     | Level 3 |            |   |     | Total |            |   |
|:-------------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-----------:|:--|:----|:------|-----------:|:--|
| Balance at December 31, 2023                     |     | $       | - |     | $       | - |     | $       |    320,117 |   |     |       |    320,117 |   |
| Reclassification of warrant liability to equity  |     |         | - |     |         | - |     |         |   (320,117 | ) |     |       |   (320,117 | ) |
| Balance at February 13, 2024                     |     | $       | - |     | $       | - |     | $       |          - |   |     | $     |